Category Research

Dermal Fillers Market 2023-2035: Hyaluronic Acid Innovation Drives Expansion – ResearchAndMarkets.com

Introducing the latest addition to ResearchAndMarkets.com’s offerings, the report on the “Global Dermal Fillers Market, 2023-2035”. Estimated at $3 billion in 2023, the global dermal fillers market is poised for robust growth, projected at a compound annual growth rate (CAGR)…

Read MoreDermal Fillers Market 2023-2035: Hyaluronic Acid Innovation Drives Expansion – ResearchAndMarkets.com

FDA Approves Ipsen’s Onivyde® as Promising First-Line Treatment for Metastatic Pancreatic Adenocarcinoma

Ipsen (Euronext: IPN; ADR: IPSEY) has announced the approval by the U.S. Food and Drug Administration (FDA) of the supplemental new drug application for Onivyde® (irinotecan liposome injection) in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) as a first-line therapy…

Read MoreFDA Approves Ipsen’s Onivyde® as Promising First-Line Treatment for Metastatic Pancreatic Adenocarcinoma

U.S. FDA Conducts Inspection of Lupin’s Dabhasa Facility, Finds No Observations

Lupin Limited, a leading global pharmaceutical company, announced today that the United States Food and Drug Administration (U.S. FDA) has successfully completed a Good Manufacturing Practice (GMP) Inspection of its Active Pharmaceutical Ingredient (API) manufacturing facility situated in Dabhasa, India.…

Read MoreU.S. FDA Conducts Inspection of Lupin’s Dabhasa Facility, Finds No Observations

Baxter Broadens Pharmaceutical Portfolio with Fresh Injectable Offerings in the U.S.

Baxter International Inc. (NYSE:BAX), renowned globally for its excellence in injectables, anesthesia, and drug compounding, has unveiled a significant expansion of its Pharmaceuticals portfolio with the introduction of five new injectable products in the United States. Alok Sonig, Executive Vice…

Read MoreBaxter Broadens Pharmaceutical Portfolio with Fresh Injectable Offerings in the U.S.

FDA Grants Roche Breakthrough Device Designation for Blood Test Advancing Early Alzheimer’s Disease Detection

Roche (SIX: RO, ROG; OTCQX: RHHBY) disclosed today that its Elecsys pTau217 assay has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). Developed in collaboration with Eli Lilly and Company, this blood test aims to…

Read MoreFDA Grants Roche Breakthrough Device Designation for Blood Test Advancing Early Alzheimer’s Disease Detection

Orion Research Assistants Striving to Combat Cancer and Alleviate Pain: “Our Breakthrough Discovery Holds Promise for Shaping Future Research

Mira Leppänen-Mattelmäki, a Research Associate in Orion’s pain team, finds her greatest motivation in the potential impact their work may have on patients. For Minna Vuorenmaa, a Research Assistant in the cancer research team, the meaningfulness of aiding patients fuels…

Read MoreOrion Research Assistants Striving to Combat Cancer and Alleviate Pain: “Our Breakthrough Discovery Holds Promise for Shaping Future Research